
Dollars for Docs Payments Approach $300 Million
by Charles Ornstein , Tracy Weber and Dan Nguyen
ProPublica, Dec. 22, 2010, 1:36 p.m.
Today we’ve added another $13 million in payments to our Dollars for Docs database of drug-company spending on doctors and other health professionals. That brings the total to nearly $295 million.
ProPublica launched Dollars for Docs in October, creating the most accessible accounting yet of pharmaceutical payments to doctors for speaking, consulting and other duties. It includes disclosures from Eli Lilly & Co., AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Pfizer and Cephalon for various periods of 2009 and 2010.
The new payments were made by Glaxo and Ortho-McNeil, a division of Johnson & Johnson, in the third quarter of this year. Other Johnson & Johnson subsidiaries have yet to update spending totals beyond the first quarter.
Interestingly, Glaxo’s spending on speaking and consulting dropped markedly in the third quarter compared to its average in prior quarters. In the past, the company paid large amounts to doctors to promote its diabetes drug Avandia. But the U.S. Food and Drug Administration severely restricted the drug’s use in September amid concerns about its heart attack risks.



